Patents by Inventor David Magrez

David Magrez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260240800
    Abstract: The present invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of elafibranor, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic acid (GFT1007), and a pharmaceutically acceptable salt of elafibranor or GFT1007, for use in a method for treating primary biliary cholangitis (PBC) in a subject having PBC with a baseline plasma alkaline phosphatase (ALP) level of more than 1.67×ULN and at most 3×ULN.
    Type: Application
    Filed: April 14, 2026
    Publication date: August 20, 2026
    Inventors: Pascal Birman, Alice Roudot, David Magrez
  • Patent number: 12589086
    Abstract: The invention relates to a pharmaceutical composition comprising elafibranor or a pharmaceutically acceptable salt thereof, for use to treat primary biliary cholangitis (PBC) in a subject intolerant to ursodeoxycholic acid (UDCA).
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: March 31, 2026
    Assignee: Genfit
    Inventors: Pascal Birman, Alice Roudot, David Magrez, Benoit Noel
  • Publication number: 20230301951
    Abstract: The invention relates to a pharmaceutical composition comprising elafibranor or a pharmaceutically acceptable salt thereof, for use to treat primary biliary cholangitis (PBC) in a subject intolerant to ursodeoxycholic acid (UDCA).
    Type: Application
    Filed: August 25, 2021
    Publication date: September 28, 2023
    Inventors: Pascal Birman, Alice Roudot, David Magrez, Benoit Noel